Jeff Yass’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Jeff Yass’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,498	Closed	-$4.46K	–	13662
2023 Q1	$4.46K	Sell	1,498 -608	-29%	-$2.24K	﹤0.01%	12317
2022 Q4	$10.5K	Buy	+2,106	New	+$8.06K	﹤0.01%	11933
2022 Q3	–	Sell	-1,253	Closed	-$9K	–	14517
2022 Q2	$9K	Buy	+1,253	New	+$11.4K	﹤0.01%	12539

Other funds holding LABP

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jeff Yass's LABP Position: Q2 2023 in Review

Jeff Yass sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 1,498 shares — an estimated $4.46K sold.

Jeff Yass first reported a position in LABP in Q2 2022 and held it in 3 quarters. The position peaked at $10.5K in Q4 2022. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

Jeff Yass reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jeff Yass sold 1,498 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $4.46K.
Jeff Yass first reported a position in Landos Biopharma, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Jeff Yass's Landos Biopharma, Inc. Common Stock position peaked at $10.5K in Q4 2022.
8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.